Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
Dyslipidemia treatment is of major importance in reducing the risk of atherosclerotic cardiovascular disease (ASCVD), which is still the most common cause of death worldwide. During the last decade, a novel lipid-lowering drug category has emerged, i.e., proprotein convertase subtilisin/kexin type 9...
Saved in:
Main Authors: | Niki Katsiki (Author), Michal Vrablik (Author), Maciej Banach (Author), Ioanna Gouni-Berthold (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Monocyte/high-density lipoprotein cholesterol, neutrophil/high-density lipoprotein cholesterol, and lymphocyte/high-density lipoprotein cholesterol ratios as new inflammatory markers in rosacea
by: Bülent Nuri Kalaycı
Published: (2023) -
Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b for cardiovascular risk assessment - What is the right choice?
by: Shrikanth N Hegde
Published: (2020) -
Lipoprotein Metabolism, Dyslipidemia, and Lipid-Lowering Therapy in Women: A Comprehensive Review
by: Jakub Michal Zimodro, et al.
Published: (2024) -
Triglyceride to high-density lipoprotein cholesterol and low-density lipoprotein cholestrol to high-density lipoprotein cholesterol ratios are predictors of cardiovascular risk in Iranian adults: Evidence from a population-based cross-sectional study
by: Karimollah Hajian-Tilaki, et al.
Published: (2020) -
The N‐Acetylgalactosamine‐conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low‐density lipoprotein cholesterol reductions
by: Dario Lehoux, et al.
Published: (2023)